key: cord-0952575-1kijiu1h
authors: Lopez Bernal, J.; Andrews, N.; Gower, C.; Stowe, J.; Tessier, E.; Simmons, R.; Ramsay, M.
title: Effectiveness of BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on mortality following COVID-19
date: 2021-05-18
journal: nan
DOI: 10.1101/2021.05.14.21257218
sha: 848b1614302f57f4988cc142a9db89a4fed8aa19
doc_id: 952575
cord_uid: 1kijiu1h

We estimated risk of death in vaccinated compared to unvaccinated COVID-19 cases. Cases vaccinated with 1 dose of BNT162b2 had 44% reduced risk of death, 55% with 1 dose of ChAdOx1, and 69% with 2 doses of BNT162b2. This is on top of the protection provided against becoming a case.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) f  i  r  s  t  t  o  e  s  t  i  m  a  t  e  f  o  r  t  h  e  e  f  f  e  c  t  i  v  e  n  e  s  s  o  f  C  h  A  d  O  x  1  a  g  a  i  n  s  t  m  o  r  t  a  l  i  t  y  a  n  d  s  u  g  g  e  s  t  s  t  h  a  t  a  s  i  n  g  l  e  d  o  s  e  o  f  f  e  r  s  s  i  m  i  l  a  r  l  e  v  e  l  s  o  f  p  r  o  t  e  c  t  i  o  n  t  o  B  N  T  1  6  2  b  2  .   W  e  f  o  u  n  d  t  h  a  t  a  l  t  h  o  u  g  h  b  o  t  h  v  a  c  c  i  n  e  s  p  r  o  v  i  d  e  d  a  d  d  i  t  i  o  n  a  l  p  r  o  t  e  c  t  i  o  n  a  g  a  i  n  s  t  m  o  r  t  a  l  i  t  y  o  v  e  r  a  l  l  ,  a  m  o  n  g  c  a  r  e  h  o  m  e  r  e  s  i  d  e  n  t  s  w  h  o  r  e  c  e  i  v  e  d  a  s  i  n  g  l  e  d  o  s  e  o  f  t  h  e  P  f  i  z  e  r  v  a  c  c  i  n  e  ,  t  h  e  e  f  f  e  c  t  w  a  s  s  m  a  l . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101/2021.05.14.21257218 doi: medRxiv preprint

Effectiveness of BNT162b2 mRNA vaccine against infection and COVID-19 vaccine coverage in healthcare workers in England

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of Long-Term Care Facilities (VIVALDI study)

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. The New England journal of medicine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Technical summary: Public Health England data series on deaths in people with COVID-19 2020

COVID-19 -high risk shielded patient list identification methodology 2020

Public Health England vaccine effectiveness report -March 2021: Public Health England

Nationwide Vaccination Campaign with BNT162b2 in Israel Demonstrates High Vaccine Effectiveness and Marked Declines in Incidence of SARS-CoV-2 Infections and COVID-19 Cases, Hospitalizations, and Deaths